e-Therapeutics plc Director/PDMR Shareholding (9810G)
June 02 2017 - 3:00AM
UK Regulatory
TIDMETX
RNS Number : 9810G
e-Therapeutics plc
02 June 2017
E-THERAPEUTICS PLC
("e-Therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY
PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Oxford, UK, 2 June 2017 - e-Therapeutics plc (AIM: ETX), the
drug discovery company, announces that it has today received
notifications from three of its directors that they have purchased,
in aggregate, 2,830,000 shares in the Company at a price of 6 pence
per share. The purchases took place on 1 June 2017.
The number of ordinary shares purchased by each director is set
out below:
Director Number
of shares
purchased
----------------- -----------
Iain Ross 1,000,000
----------------- -----------
Ray Barlow 830,000
----------------- -----------
Steve Medlicott 1,000,000
----------------- -----------
Following these trades, the interests of those directors in
ordinary shares of ETX are as follows:
Director Number Percentage
of shares of issued
held share
capital
----------------- ----------- -----------
Iain Ross 1,000,000 0.37%
----------------- ----------- -----------
Ray Barlow 830,000 0.31%
----------------- ----------- -----------
Steve Medlicott 1,250,000 0.47%
----------------- ----------- -----------
The notifications below, made in accordance with the
requirements of the EU Market Abuse Regulation, provide further
details:
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------
a) Name Iain Ross
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Non-Executive Chairman
--- ------------------------ ----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name e-Therapeutics plc
--- ------------------------ ----------------------------------
b) LEI 21380049RHSSJXWKYT18
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ------------------------------------------------------------
a) Description of Ordinary Shares of 0.1 pence
the financial
instrument, type ISIN: GB00B2823H99
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Purchase of shares
transaction
--- ------------------------ ----------------------------------
c) Price(s) and 1,000,000 ordinary shares at a
volume(s) price of 6 pence per share
--- ------------------------ ----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------
e) Date of the transaction 1 June 2017
--- ------------------------ ----------------------------------
f) Place of the London Stock Exchange, AIM (XLON)
transaction
--- ------------------------ ----------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- -------------------------------------------------------------
a) Name Ray Barlow
--- ------------------------ -----------------------------------
2 Reason for the notification
--- -------------------------------------------------------------
a) Position/status Chief Executive Officer
--- ------------------------ -----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ -----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------
a) Name e-Therapeutics plc
--- ------------------------ -----------------------------------
b) LEI 21380049RHSSJXWKYT18
--- ------------------------ -----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- -------------------------------------------------------------
a) Description of Ordinary Shares of 0.1 pence
the financial
instrument, type ISIN: GB00B2823H99
of instrument
Identification
code
--- ------------------------ -----------------------------------
b) Nature of the Purchase of shares
transaction
--- ------------------------ -----------------------------------
c) Price(s) and 830,000 ordinary shares at a price
volume(s) of 6 pence per share
--- ------------------------ -----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ -----------------------------------
e) Date of the transaction 1 June 2017
--- ------------------------ -----------------------------------
f) Place of the London Stock Exchange, AIM (XLON)
transaction
--- ------------------------ -----------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ------------------------------------------------------------
a) Name Steve Medlicott
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Finance Director
--- ------------------------ ----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name e-Therapeutics plc
--- ------------------------ ----------------------------------
b) LEI 21380049RHSSJXWKYT18
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- ------------------------------------------------------------
a) Description of Ordinary Shares of 0.1 pence
the financial
instrument, type ISIN: GB00B2823H99
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Purchase of shares
transaction
--- ------------------------ ----------------------------------
c) Price(s) and 1,000,000 ordinary shares at a
volume(s) price of 6 pence per share
--- ------------------------ ----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------
e) Date of the transaction 1 June 2017
--- ------------------------ ----------------------------------
f) Place of the London Stock Exchange, AIM (XLON)
transaction
--- ------------------------ ----------------------------------
For further information, please contact:
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993
Iain Ross, Chairman 883 125
Steve Medlicott, Finance www.etherapeutics.co.uk
Director
Numis Securities Limited Tel: +44 (0) 207
Michael Meade / Freddie 260 1000
Barnfield www.numis.com
(Corporate Finance)
James Black (Corporate
Broking)
Instinctif Partners Tel: +44 (0) 207
Melanie Toyne Sewell / 457 2020
Alex Shaw Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics is a drug discovery company with a unique and
proprietary in silico discovery platform. The Company is applying
its computational platform to the discovery of new drug candidates
for which it can secure robust intellectual property rights.
The therapeutic focus of the Company's discovery activity is in
areas of complex disease with unmet medical need, including
immuno-oncology. The business model is to partner these preclinical
drug candidates.
e-Therapeutics is headquartered in Oxford. For more information
about the Company please visit www.etherapeutics.co.uk.
DSHLIFVDRDIFIID
(END) Dow Jones Newswires
June 02, 2017 04:00 ET (08:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024